Shuli Cheng1, Bronwyn Jenkins2,3, Nicole Limberg4, Elspeth Hutton1,5. 1. Department of Neurology, Alfred Health, Melbourne, VIC, Australia. 2. Department of Neurology, Royal North Shore Hospital, Sydney, NSW, Australia. 3. Department of Medicine, University of Sydney, Sydney, NSW, Australia. 4. Migraine Specialist Brisbane, Brisbane, QLD, Australia. 5. Central Clinical School, Monash University, Melbourne, VIC, Australia.
Abstract
OBJECTIVE: To determine the effectiveness and safety of erenumab in patients with chronic migraine in the real-world setting of 3 headache centers in Australia. METHODS: Patients with migraine were prescribed erenumab (70 or 140 mg) in the setting of either a product familiarization program or paid access to the medication in 3 headache centers in Australia. We obtained baseline and monthly prospective data on monthly headache days, monthly migraine days, monthly triptan use days, monthly codeine use days, Headache Impact Test-6 scores, and adverse reactions. In this paper, we present our data at 3 and 6 months in our subgroup of patients with chronic migraine with and without medication overuse. RESULTS: A total of 170 patients with chronic migraine were prescribed erenumab in the 3 headache centers. At 3 months, 100/170 (58.8%) had 50% or greater reduction in monthly migraine days. At 6 months, 79/170 (46.5%) had 50% or greater reduction in monthly migraine days. At 6 months, there was a mean reduction in monthly headache days of 9.2 days, a mean reduction in monthly migraine days of 10.2 days. There were few adverse events reported. CONCLUSION: This is the first report from 3 Australian headache centers about erenumab in the real world. Our analysis has supported erenumab as an effective and well-tolerated migraine preventative therapy for patients with chronic migraine who have failed many preventative therapies.
OBJECTIVE: To determine the effectiveness and safety of erenumab in patients with chronic migraine in the real-world setting of 3 headache centers in Australia. METHODS:Patients with migraine were prescribed erenumab (70 or 140 mg) in the setting of either a product familiarization program or paid access to the medication in 3 headache centers in Australia. We obtained baseline and monthly prospective data on monthly headache days, monthly migraine days, monthly triptan use days, monthly codeine use days, Headache Impact Test-6 scores, and adverse reactions. In this paper, we present our data at 3 and 6 months in our subgroup of patients with chronic migraine with and without medication overuse. RESULTS: A total of 170 patients with chronic migraine were prescribed erenumab in the 3 headache centers. At 3 months, 100/170 (58.8%) had 50% or greater reduction in monthly migraine days. At 6 months, 79/170 (46.5%) had 50% or greater reduction in monthly migraine days. At 6 months, there was a mean reduction in monthly headache days of 9.2 days, a mean reduction in monthly migraine days of 10.2 days. There were few adverse events reported. CONCLUSION: This is the first report from 3 Australian headache centers about erenumab in the real world. Our analysis has supported erenumab as an effective and well-tolerated migraine preventative therapy for patients with chronic migraine who have failed many preventative therapies.
Authors: Luigi Francesco Iannone; Davide Fattori; Silvia Benemei; Alberto Chiarugi; Pierangelo Geppetti; Francesco De Cesaris Journal: CNS Drugs Date: 2022-02-11 Impact factor: 5.749
Authors: Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río Journal: J Headache Pain Date: 2021-07-17 Impact factor: 7.277
Authors: Stewart J Tepper; Messoud Ashina; Uwe Reuter; Yngve Hallström; Gregor Broessner; Jo H Bonner; Hernan Picard; Sunfa Cheng; Denise E Chou; Feng Zhang; Jan Klatt; Daniel D Mikol Journal: J Headache Pain Date: 2021-07-23 Impact factor: 7.277